Bronchopulmonary dysplasia is a leading cause of mortality and morbidity in preterm infants despite improved treatment modalities. Pentoxifylline, a phosphodiesterase inhibitor, inhibits multiple processes leading to neonatal hyperoxic lung injury, including inflammation, coagulation and edema. Using a preterm rat model, we investigated the effects of pentoxifylline on hyperoxia-induced lung injury and survival. Preterm rat pups were exposed to 100% oxygen and injected subcutaneously with 0.9% saline or pentoxifylline 75 mg/kg twice a day. On day 10, lung tissue was harvested for histology, fibrin deposition, and mRNA expression, and bronchoalveolar lavage fluid was collected for total protein concentration. Pentoxifylline treatment increased mean survival by 3 days (p=0.0018) and reduced fibrin deposition by 66% (p<0.001) in lung homogenates compared to untreated hyperoxia-exposed controls. Monocyte chemoattractant protein-1 expression in lung homogenates was decreased, but the expression of TNF-α, IL-6, matrix metalloproteinase-12, tissue factor, and plasminogen activator inhibitor-1 was similar in both groups. Total protein concentration in bronchoalveolar lavage fluid was decreased by 33% (p=0.029) in the pentoxifylline group. Pentoxifylline treatment attenuates alveolar fibrin deposition and prolongs survival in preterm rat pups with neonatal hyperoxic lung injury, probably by reducing capillary-alveolar protein leakage.
Introduction
Bronchopulmonary dysplasia (BPD) is a leading cause of mortality and morbidity in preterm newborn infants with respiratory distress syndrome despite improved treatment modalities (22).
Nowadays, BPD, defined by oxygen requirement at 36 weeks of gestation, affects especially newborn infants born at less than 30 weeks of gestation with a birth weight less than 1,200 g (1;
15). BPD is a multifactorial disease, characterized by decreased alveolarization and abnormal vascularization, and associated with oxidative stress, barotrauma, surfactant deficiency, inflammation, alveolar fibrin deposition, nutrition, and genetic background (13) (14) (15) . The (im)balance between initiating factors and host characteristics probably determines whether BPD will actually occur in the preterm infant.
The inflammatory response and coagulation cascade play important roles in the pathophysiology of acute and chronic lung disease in newborn infants and animal models. Increased levels of proinflammatory cytokines (TNF-α and IL-6) have been observed in tracheal aspirates of infants developing BPD (16) (17) (18) . In addition, intra-alveolar and intravascular fibrin deposition has been detected in acute lung injury (2; 10; 11) . In animal models, including premature baboons, neonatal mice and rats, exposure to hyperoxia results in chronic lung disease which closely resembles BPD in preterm infants (3; 5; 8; 28; 37; 39) .
In a previous study, we demonstrated that genes involved in inflammation, coagulation, fibrinolysis, fibrosis, extracellular matrix turnover, alveolar development, edema, cell cycle, and oxidative stress response are differentially expressed in preterm rats with BPD secondary to exposure to hyperoxia (37) . Expression profiles were in line with histopathology. The importance of extravascular fibrin deposition and upregulation of the coagulation cascade and inflammatory response in this model suggests a potential role for compounds with anti-inflammatory and anticoagulant properties. The methylxantine derivative pentoxifylline (PTX) has been used in the treatment of peripheral arterial diseases for its positive effects on the capillary blood flow by reducing blood viscosity and improving erythrocyte deformability (27; 38 , Bayer AG, Leverkusen, Germany). To avoid post-mortem fibrin deposition in the lungs, heparin (100 units, Leo Pharma, Breda, the Netherlands) was injected intraperitoneally.
After 5 min, pups were exsanguinated by transection of the abdominal blood vessels. The thoracic cavity was opened and the lungs were removed, snap-frozen in liquid nitrogen and stored at -80°C until use for real time RT-PCR or the fibrin deposition assay. For histology studies, the trachea was cannulated (Bioflow 0.6 mm i.v. catheter, Vygon, Veenendaal, the Netherlands) and the lungs were fixed in situ via the trachea cannula with buffered formaldehyde (3.8% paraformaldehyde in phosphate buffered saline, pH 7.4) at 25 cm H 2 O pressure for 3 min.
Lungs were removed, fixed additionally in formaldehyde for 24 h at 4°C, and embedded in paraffin after dehydration in a graded alcohol series and xylene.
Brochoalveolar lavages
Pups were anesthesized with an intraperitoneal injection of ketamine and xylazine and injected intraperitoneally with heparin. A cannula (Bioflow 0.6 mm i.v. catheter, Vygon, Veenendaal, the Netherlands) was positioned in the trachea and the pups were exsanguinated by transection of the abdominal blood vessels. Lungs were slowly lavaged four times with 500 µl NaCl 0.9%, 1 as chromogenic substrate, and counterstained briefly with hematoxylin.
Fibrin detection assay
Fibrin deposition in lungs was detected as described previously (40) . Briefly, frozen lungs were homogenized with an Ultra-Turrax T8 tissue homogenizer (IKA-Werke, Staufen, Germany) for 1 min at full speed in a cold 10 mM sodium phosphate buffer (pH 7.5), containing 5 mM EDTA, 100 mM ε-aminocaproic acid, 10 U/ml aprotinin, 10 U/ml heparin, and 2 mM phenylmethanesulfonyl fluoride. The homogenate was incubated for 16 h on a top over top rotor at 4°C. After centrifugation (10,000 rpm, 4°C, 10 min), the pellet was resuspended in extraction buffer (10 mM sodium phosphate buffer [pH 7.5], 5 mM EDTA and 100 mM ε-aminocaproic acid), and recentrifuged. Pellets were suspended in 3M urea, extracted for 2 h at 37°C, and centrifuged at 14,000 rpm for 15 min. After the supernatant was aspirated and discarded, the pellet was dissolved at 65°C in reducing sample buffer (10 mM Tris pH 7.5, 2% SDS, 5%
glycerol, 5% β-mercaptoethanol, and 0.4 mg/ml bromophenol blue) for 90 min with vortexing every 15 min. Hereafter, samples were subjected to SDS-PAGE (7.5%; 5% stacking) and blotted onto PVDF membrane (Immobilon-P, Millipore, Bredford, MA, USA). The 56 kD fibrin β-chains were detected with a monoclonal anti-human fibrin antibody (59D8, Boston Research Services
Company, Winchester, MA, USA) that specifically recognizes β-fibrin (9; 40), using chemiluminescence (ECL; Amersham, Arlington Heights, IL, USA) and Kodak X-OMAT TM Blue XB-1 films (Kodak, Rochester, NY, USA). Exposures were quantified with a Biorad GS-800 calibrated densitometer using the Quantity One, version 4.4.1 software package (Biorad, Veenendaal, the Netherlands). Fibrin deposition was quantified in lungs of at least 4 rats per experimental group. As a reference, fibrin standards were generated from rat fibrinogen (Sigma, St. Louis, MO, USA). After rat fibrinogen was solubilized in two-thirds strength PBS (pH 7.4), human α-thrombin (Sigma, St. Louis, MO, USA) was added, vortexed, and incubated at 37°C for 10 min. After addition of 2x SDS sample buffer the fibrin sample was vortexed, incubated at 65°C for 90 min, and aliquots were frozen at -80°C until use.
Real-time RT-PCR
Total RNA was isolated from lung tissue homogenates using guanidium-phenol extraction (RNAzol TM , Campro Scientific, Veenendaal, the Netherlands). Briefly, after tissue homogenization in RNAzol B, RNA was isolated using phenol-chloroform extraction and isopropanol precipitation. The RNA sample was dissolved in RNase-free water and quantified spectrophotometrically. The integrity of the RNA was studied by gel electrophoresis on a 1% Detection System version 1.9 software and quantified using the comparative threshold cycle method with β-actin as a housekeeping gene reference (26).
Protein assay
Total protein concentration was measured in bronchoalveolar lavage fluid (BALF) using the Dc Protein Assay (Biorad, Veenendaal, the Netherlands) according to the manufacturer's instructions. The detection limit was 31 µg/ml.
Statistical analysis
Values are expressed as mean ± SEM. Differences between groups were analyzed with the Student t test. For comparison of survival curves, Kaplan-Meier analysis followed by a log rank test was performed. P-values <0.05 were considered statistically significant.
Results

Fibrin deposition
Since fibrin deposition correlates well with the severity of tissue damage in hyperoxia-induced lung injury, we quantified fibrin deposition by Western Blot analysis in lungs after exposure to different oxygen concentrations to determine the optimal experimental conditions for intervention. Fibrin deposition in lung homogenates of preterm rat pups exposed to 60%, 80%
and 100% oxygen is shown in Figure 1 , panel A. Significant fibrin deposition was absent in lungs of pups exposed to 60% and 80% oxygen for 14 days (Figure 1, panel B) . However, fibrin deposition increased from 18 ± 8 in room air-exposed pups to 296 ± 42 ng fibrin per mg of tissue in lungs of pups exposed to 100% oxygen for 10 days (Figure 1 , panel B, p<0.001),
demonstrating that this is the optimal experimental condition. Therefore, intervention studies were performed in preterm rat pups exposed to 100% oxygen. Treatment of oxygen-exposed pups with PTX for 10 days,resulted in a reduction of fibrin deposition from 296 ± 42 in oxygenexposed controls to 100 ± 23 ng fibrin per mg of tissue in lungs of PTX treated pups exposed to 100% oxygen ( Figure 1, panel B, p<0 .001). The localization of fibrin deposits in the lungs was studied immunohistochemically on formaldehyde fixed paraffin sections. Fibrin deposits were mainly observed in the extravascular compartment in the alveolar lumen and were associated with the alveolar wall ( Figure 1, panel D) . In control lungs fibrin deposits were absent ( Figure 1 ,
mRNA expression in lung homogenates
Since PTX has anti-inflammatory, anti-coagulant and anti-fibrinolytic properties, we studied mRNA expression of key enzymes involved in these processes in lung homogenates after lung injury by hyperoxia. TNF-α mRNA expression did not change after oxygen exposure (p=0.934) 
BALF
Total protein concentration was measured in BALF as a marker for capillary leakage. Protein concentration on postnatal day 10 was 103 ± 7 µg/ml in pups exposed to room air, 328 ± 37 µg/ml in pups exposed to 100% oxygen treated with saline ( Figure 3 ; p<0.001), and 218 ± 18 µg/ml in pups exposed to 100% oxygen treated with PTX ( Figure 3 ; p=0.029). PTX treatment decreased the white blood cell count in BALF from 55 ± 16 x 10 5 cells/ml in oxygen-exposed pups treated with saline to 16 ± 5 x 10 5 cells/ml in oxygen-exposed pups treated with PTX (p=0.05).
Survival
Survival of PTX treated hyperoxia-exposed pups was prolonged compared to oxygen-exposed controls (Figure 4 ; p=0.0018). After 12 days of oxygen exposure, 73% of the controls had died versus only 20% of the PTX pups. The mean survival of preterm oxygen-exposed rat pups treated with PTX was prolonged by 3 days. Subcutaneous injection of room air-exposed pups (n=5) with 0.9% saline did not lead to illness or mortality the first four weeks after birth (data not shown).
Discussion
The reported experiments show that pentoxifylline (PTX) treatment reduces fibrin deposition 3-fold and prolongs survival by 3 days in preterm rat pups with hyperoxia-induced lung injury. Conflicting results have been found on survival after PTX treatment in lung injury models. In contrast to our findings, PTX treatment did not prolong survival in adult rats after exposure to >95% oxygen (25). This discrepancy may be explained by the difference in oxygen tolerance between neonates and adults in combination with a lower PTX dosage used in the adult rat experiments. Beneficial effects of PTX treatment on survival were reported after endotoxemia, even at low dosages, in mice (42).
We only found an effect of PTX on MCP-1 mRNA expression, but not on TNF-α and IL-6
expression. Many other in vitro and in vivo studies demonstrate that PTX inhibits the expression of pro-inflammatory cytokines (6; 19; 23; 24; 29; 32; 34; 35; 42). These studies emphasize the attenuating effect of PTX on TNF-α and IL-6, the key pro-inflammatory targets of PTX.
Moreover, three studies implicate that inhibition of the release of TNF-α is the most important outcome predictor in endotoxemia (24; 34; 42). A possible explanation for this discrepancy might be that TNF-α does not play the same pivotal role in the inflammatory response in neonatal hyperoxia-induced lung injury as it does in endotoxemia. The finding that TNF-α was not significantly different between room air-exposed and oxygen-exposed pups strengthens this hypothesis. In contrast, the importance of MCP-1 has been demonstrated in a hyperoxiainduced BPD model. Newborn rats exposed to hyperoxia were injected with anti-MCP-1 resulting in the prevention of neutrophil influx and reduced protein oxidation (36) . We assume that the room air control; C: oxygen-exposed pup treated with 0.9% saline; P: oxygen-exposed pup treated with PTX). Lung homogenates of pups exposed to 60% and 80% oxygen were not diluted, whereas lung homogenates of pups exposed to 100% oxygen were diluted 1:5. Fibrin standards were used to quantify fibrin deposition in the lung homogenates. Panel B:
Quantification of fibrin deposition in lung homogenates on day 10. Experimental groups include room air controls (white bars), oxygen-exposed pups treated with 0.9% saline (black bars) and oxygen-exposed pups treated with PTX (dotted bars). Oxygen treated pups were exposed to 60% oxygen (n=4), 80% oxygen (n=4) and 100% oxygen (n=20). Data are expressed as mean ± SEM. ***: p<0.001, Oxygen vs. room air-exposed controls; ∆∆∆: p<0.001, PTX vs. oxygen- Data are expressed as mean ± SEM of 6 (room air) or 20 (both oxygen-exposed groups) rats.
*:p<0.05, **:p<0.01, ***:p<0.001, Oxygen vs. room air-exposed controls; ∆: p<0.05, PTX vs.
oxygen-exposed controls. 
